The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

NCT04206787 · clinicaltrials.gov ↗

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-squamous, Non-Small Cell Lung Cancer

Interventions

DRUG: Afatinib

Sponsor

Boehringer Ingelheim